Publications by authors named "Toshiaki Nishihata"
Objective: To evaluate the efficacy and safety of a single-dose intravitreal umedaptanib pegol (anti-FGF2, investigational new drug) for the treatment of neovascular age-related macular degeneration (nAMD).
Methods: Nine participants who had a diagnosis of refractory nAMD were enrolled and received a single intravitreal injection of umedaptanib pegol at increasing doses of 0.2, 1.
Background/objective: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are the first-line treatment for exudative age-related macular degeneration (nAMD). Due to the limitations of these standard therapies, targeting alternative mechanisms of action may be helpful for treatment of this very common disease. Here, we investigated an anti-fibroblast growth factor-2 (FGF2) aptamer, umedaptanib pegol, a next generation therapeutic for the treatment of nAMD.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers are exploring a new treatment target, fibroblast growth factor 2 (FGF2), which plays a role in both blood vessel growth and fibrosis, suggesting that it could be effective for AMD.
- * The anti-FGF2 aptamer RBM-007 has shown promising results in animal studies, effectively inhibiting unwanted blood vessel growth and scarring, with better effects on the eye than existing anti-VEGF therapies.